手性胺拆分法制备雷美替胺

以(S)-苯乙胺为拆分剂,对合成雷美替胺(1)的中间体(R,S)-2-{1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基}乙酸[(R,S)-2]进行拆分得(S)-2;(S)-2再经3步反应合成了(S)-1,ee值为97%。以L-(-)-二苯甲酰酒石酸为拆分剂,对(R,S)-2-{1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基}乙胺[(R,S)-3]进行拆分得(S)-3;(S)-3再经1步反应合成了(S)-1,ee值为99%。1的结构经1H NMR确证。     

替格瑞洛的合成工艺改进

以2-丙硫基-4,6-二氢-5-氨基嘧啶和2-{［(3aR,4S,6R,6aS)-6-氨基-2,2-二甲基四氢-3aH-环戊基［d］［1,3］二氧-4-基］氧}-1-乙醇L-酒石酸盐为原料,经C-N偶联,亲核取代和环合反应制得2-{［(3aR,4S,6R,6aS)-6-(7-氯-5-丙硫基-3H-［1,2,3］三唑［4,5-d］嘧啶-3-基)-2,2-二甲基四氢-3aH-环戊基［d］［1,3］二氧-4-基］氧}-1-乙醇(4); 4与(1R,2S)-2-(3,4-二氟苯基)环丙胺D-扁桃酸盐经亲核取代反应后酸解脱除丙酮叉保护基合成替格瑞洛,总收率58.7%,纯度99.2%,其结构经¹H NMR, MS(ESI)和XRD确证。     

酸功能化离子液体催化合成2-叔丁基蒽醌

以N-甲基咪唑、吡啶、1,4-丁烷磺内酯、对甲苯磺酸及硫酸为主要原料,经两步反应合成了4种酸功能化离子液体［MIM-BS］［TsO］(IL1)、 ［MIM BS］［HSO₄］(IL2)、 ［PY-BS］［TsO］(IL3)和［PY-BS］［HSO₄］(IL4),其结构和性能经¹H NMR, IR和TGA表征。以［MIM-BS］［TsO］为催化剂,催化2-(4-叔丁基苯甲酰基)苯甲酸(BB酸)合成2-叔丁基蒽醌,并对反应条件进行了优化。结果表明：IL1 0.4 g,n(IL)/n(BB酸)=0.5,于120 ℃反应9 h, 2-叔丁基蒽醌产率最高达90%,离子液体循环使用5次后催化活性无明显降低。     

手性拆分法制备雷美替胺关键中间体(S)-2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙胺

以(S)-布洛芬为拆分剂,对(R,S)-2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙胺进行拆分,获得雷美替胺的关键中间体(S)-2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙胺,ee值99%,总收率60%,其结构经¹H NMR和HR-MS（ESI）确证。     

抗丙肝药物维拉帕维的合成

以7-羟甲基-1-四氢萘酮和1-溴-4-氯-苯甲醛为起始原料,经14步反应合成了抗丙肝新药维拉帕维--甲基（2S）-1-【(2S,5S)-2-【9{2［（2S,4S）-1-（2R)-2-［（甲氧基羰基）氨基］-2-苯乙酰基-4-（甲氧基甲基）吡咯烷-2-基］-1H-咪唑 5 基} 1,11-二氢异色烯［4′,3′ :6,7］萘并［1,2-d］咪唑-2-基-5-甲基吡咯烷-1-基】-3-甲基-1-氧丁烷-2-基】氨基甲酸酯,总产率10.14%,其结构经¹H NMR和ESI-MS确证。     

盐酸普拉克索的合成工艺改进

以(S)-2,6-二氨基-4,5,6,7-四氢苯并噻唑（3）为原料,经缩合、还原反应制得普拉克索（2）; 2与盐酸成盐后制得盐酸普拉克索一水合物（1）,其结构经¹H NMR, ¹³C NMR, IR和MS（ESI）确证。研究了溶剂、反应温度、投料比γ［n(3) : n(正丙醛)］、析晶终止温度和精制降温速度对1收率的影响。结果表明：在最佳反应条件（无水甲醇为溶剂,γ=1.0 : 1.8,于-15~-20 ℃反应,析晶终止温度为-5~-10 ℃）下,最高收率可达61.5%。     

2,4-二硝基苯磺酰胺的合成工艺改进

以2,4-二硝基苯胺为原料,依次经重氮化和磺化反应制得2,4-二硝基苯磺酰氯(3); 3与氨水反应合成了2,4-二硝基苯磺酰胺(4),其结构经¹H NMR, ¹³C NMR, EI-MS和元素分析确证。研究了反应时间,反应温度,溶剂,物料比{r［n(氨水):n(3)］}和加料次序对4收率的影响。结果表明：在最佳反应条件［THF为溶剂,氨水75 mmol, r=1.5,于10~30 ℃反应3 h］下合成4,收率91.3%。     

一种新型噁唑烷酮类抗生素的合成

以2,4-二溴吡啶为原料,经Weinreb酰胺酰化、Noyori不对称氢转移反应、脱Boc保护基、环化、Suzuki偶联、磷酸单酯化及成盐共七步反应制得一种新型噁唑烷酮类抗生素【【(3R,3aS)-7-{6-［(S)3-甲基-2-噁唑烷酮-5-基］吡啶-3-基}-1-氧-1,3,3a,4-四氢苯并［b］噁唑［3,4-d］［1,4］噁嗪-3-基】甲基】磷酸单酯二钠盐,其结构经¹H NMR, ¹³C NMR和HR-MS（ESI）确征,总收率7%,纯度99.7%。     

新型磷-氮有机金属阻燃剂的合成及其热稳定性

以γ-氨丙基三乙氧基硅烷(1)和二苯基氯化膦(2)为原料,经取代反应制得N-(二苯基膦基)-1,1-二苯基-N-［3-(三乙氧基甲硅烷)丙基］膦氮配体(3); 3与六水合氯化镍(4)反应合成了一种新型的磷-氮有机金属阻燃剂(5),其结构经¹H NMR, ³¹P NMR和FT-IR表征。研究了物料比［r=n(2) : n(1)］、溶剂、反应时间和反应温度对3收率的影响。结果表明：在最佳反应条件［二氯甲烷为溶剂,1 19 mmol, r=2.3,于25 ℃反应14 h］下,3收率89.5%。 TGA测试结果表明：5的初始分解温度为252 ℃, 700 ℃残炭为31.9%。     

苯并咪唑并[2,1-b]噻唑衍生物的合成

以2-巯基咪唑类化合物为原料,室温下与含有端基炔的二芳基高碘盐反应,一步合成苯并咪唑并[2,1-b]噻唑衍生物,其结构经¹H NMR、¹³C NMR、 单晶X-衍射和HR-MS表征。在最佳反应条件［n(2-巯基苯并咪唑)/n(二芳基高碘盐)=1/1,二氯甲烷为溶剂,反应12 h］下,目标化合物的产率最高为84%。同时对该反应的机理进行了详细探讨,并采用MTT法研究了目标化合物对人肝癌细胞（HepG2）生长情况的影响。结果表明：当浓度为4 μg/mL时,化合物3b具有较强的抑制HepG2细胞增殖的活性,抑制率为52%。     

水解动力学拆分3-(1-萘氧基)-1,2-环氧丙烷

研究了3-(1-萘氧基)-1,2-环氧丙烷[(R,S)-1]在Salen Co(Ⅲ)催化下的水解动力学拆分(HKR)。以转化率和ee值为指标,考察了催化剂用量、底物用量、反应温度、反应时间、溶剂种类等对HKR反应的影响。最佳HKR条件为:(R,S)-1 10 mmol,w[Salen Co(Ⅲ)]=0.75%,THF 1 mL,水0.5 eq,于25℃水解40 h,(R,S)-1的转化率为49.5%,(S)-1的ee为99.5%。     

Optical resolution by preferential crystallization of (RS)-2-benzoylamino-2-benzyl-3-hydroxypropanoic acid and its use in synthesizing optically active 2-amino-2-methyl-3-phenylpropanoic acid

To synthesize optically active 2-amino-2-methyl-3-phenylpropanoic acid (1), (RS)-2-benzoylamino-2-benzyl-3-hydroxypropanoic acid [(RS)-2] was first optically resolved using cinchonidine as a resolving agent to yield optically pure (S)- and (R)-2 in yields of about 70%, based on half of the starting amount of (RS)-2. Next, the racemic structure of (RS)-2 was examined based on melting point, solubility, IR spectrum, and binary and ternary phase diagrams, with the aim of optical resolution by preferential crystallization of (RS)-2. Results indicated that the (RS)-2 exists as a conglomerate at room temperature, although it forms a racemic compound at the melting point. The optical resolution by preferential crystallization yielded (S)- and (R)-2 with optical purities of about 90%, which were fully purified by recrystallization. After O-tosylation of (S)- and (R)-2, reduction by zinc powder and sodium iodide gave (R)- and (S)-1, respectively.     

RuCl2[(S)-P-Phos]-[(S)-DAIPEN]催化芳香酮的不对称加氢反应

研究了钌-双膦-二胺配合物催化剂RuCl2[(S)-P-Phos]-[(S)-DAIPEN] [P-Phos: 2,2',6,6'-四甲氧基-4,4'-双(二苯基膦基)-3,3'-二吡啶, DAIPEN: 1,1-二(4-甲氧苯基)-2-异丙基-1,2-乙二胺]催化芳香酮不对称加氢反应的性能, 考察了不同的碱、叔丁醇钾浓度、反应溶剂、底物/催化剂摩尔比等因素对反应活性和对映选择性的影响. 在苯乙酮、叔丁醇钾、催化剂的摩尔比为1000:20:1, 氢气压力为2 MPa, 反应温度为30 ℃时, 苯乙酮的转化率和α-苯乙醇的对映选择性(ee)分别达到了100%和88.5%, 2'-溴苯乙醇的ee 值可达97.1%.     

用循环拆分法制备手性萘乙胺

研究了1-(1-萘基)乙胺[(RS)-1]和1-(2-萘基)乙胺[(RS)-2]的循环拆分方法。以D-酒石酸为拆分剂,分别拆分(RS)-1和(RS)-2得到了(R)-1-(1-萘基)乙胺(收率31%,98%ee)和(R)-1-(2-萘基)乙胺(收率30%,98%ee),并对母液中的非目标对映异构体成功的进行了消旋化,实现了循环拆分。     

Optically active cyclohexene derivative as a new antisepsis agent: an efficient synthesis of ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242)

Two new synthetic methods were established for the efficient synthesis of optically active cyclohexene antisepsis agent, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate [(R)-1: TAK-242)]. The first method involved recrystallization from methanol of the diastereomeric mixture (6RS,1'R)-7, obtained by esterification of carboxylic acid 3 with (S)-1-(4-nitrophenyl)ethanol [(S)-5)] to give the desired isomer (6R,1'R)-7 with 99% de in 32% yield. Subsequent catalytic hydrogenolysis and esterification gave (R)-1 with >99% ee. The second method employed enantioselective hydrolysis of acetoxymethyl ester 9a (prepared by alkylation of 3 with bromomethyl acetate) with Lipase PS-D to give the eutomeric enantiomer (R)-9a with excellent enantioselectivity (>99% ee) and high yield (48%). The desired (R)-1 was then obtained by transesterification with ethanol in the presence of concentrated sulfuric acid without loss of ee. Of these, the procedure employing enzymatic kinetic resolution using Lipase PS-D is the more efficient and practical preparation of (R)-1.     

An asymmetric synthesis of (+)-grandisol, a constituent of the aggregation pheromone of the cotton boll weevil, via a kinetic resolution

A novel approach to the asymmetric synthesis of (+)-grandisol, (1R, 2S)-isopropenyl-1-methylcyclobutaneethanol, involves the use of catalytic kinetic resolution of a primary allylic alcohol, [(1RS, 5SR)-5-methylbicyclo[3.2.0]hept-2-en-2-yl] methanol. The allylic alcohol is prepared in four steps from simple achiral materials involving the use of a modified Shapiro reaction. The resolved alcohol (95% ee) is then reduced in two steps to the corresponding methyl alkene, (1S,5R)-2,5-dimethylbicyclo[3.2.0]hept-2-ene. This alkene is converted to (+)-grandisol (95% ee), in three steps, by modified literature procedures.     

Preparation of optically active threo-2-amino-3-hydroxy-3-phenylpropanoic acid (threo-beta-phenylserine) via optical resolution

To obtain optically active threo-2-amino-3-hydroxy-3-phenylpropanoic acid (1), (2RS,3SR)-2-benzoylamino-3-hydroxy-3-phenylpropanoic acid [(2RS,3SR)-2] was first optically resolved using (1S,2S)- and (1R,2R)-2-amino-1-(4-nitrophenyl)-1,3-propanediol as the resolving agents to afford (2R,3S)- and (2S,3R)-2 in yields of 73% and 66%, based on half of the starting amount of (2RS,3SR)-2. Next, the racemic structures of ammonium and some organic ammonium salts of (2RS,3SR)-2 were examined based on melting point, solubility, and infrared spectrum, with the aim of optical resolution by preferential crystallization. The benzylammonium salt of (2RS,3SR)-2 was suggested to exist as a conglomerate at room temperature, although it forms a racemic compound at the melting point. The optical resolution by preferential crystallization of the racemic salt afforded the (2R,3S)- and (2S,3R)-salts with optical purities of 90-97%. The (2R,3S)- and (2S,3R)-2 obtained from the purified salts were hydrolyzed by reflux in hydrochloric acid to give (2R,3S)- and (2S,3R)-1.     

A stereochemical anomaly: the cyclised (R)-AMPA analogue (R)-3-hydroxy-4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-5-carboxylic acid [(R)-5-HPCA] resembles (S)-AMPA at glutamate receptors

(RS)-3-Hydroxy-4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-5-carboxylic acid (5-HPCA)(), which is a conformationally constrained cyclised analogue of AMPA has previously been described as causing glutamate receptor mediated excitations of spontaneously firing cat spinal interneurons in a similar fashion to AMPA. We have now prepared the enantiomers of through chiral chromatographic resolution of (RS)-3-(carboxymethoxy)-4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-5-carboxylic acid () followed by a stereoconservative hydrolysis resulting in the enantiomers of with high enantiomeric excess (% ee [greater-than-or-equal] 99). The absolute configurations indicated by an X-ray analysis of (-)- monohydrate were confirmed by comparing observed and ab initio calculated electronic circular dichroism spectra and by stereoconservative synthesis of (S)- from (S)-AMPA, the pharmacologically active form of AMPA. The pharmacological effects at native and cloned (GluR1-4) AMPA receptors were shown to reside exclusively with (R)-(+)-, in striking contrast to the usual stereoselectivity trend among AMPA receptor agonists. The reasons for this anomalous behaviour became clear upon docking both enantiomers of to the agonist binding site of GluR2.     

(1R,3S,4S)-2-苄氧羰基-2-氮杂双环[2.2.1]庚烷-3-羧酸的合成

以(R)-(+)-α-甲基苄胺为原料,依次经缩合,Diels-Alder反应,还原,Cbz-保护和水解反应,合成了抗丙肝新药HCV NS3/4A蛋白酶拟肽类抑制剂的重要中间体——(1R,3S,4S)-2-苄氧羰基-2-氮杂双环[2.2.1]庚烷-3-羧酸,总收率66%,其结构经1H NMR和ESI-MS确证。     

Synthesis of an optically active, bicyclic 2-pyridone dipeptide mimetic

The eleven-step preparation of the bicyclic 2-pyridone dipeptide mimetic 1 [(3S)-6-(benzyloxycarbonylamino)-5-oxo-1,2,3,5-tetrahydroindolizine-3-carboxylic acid] in optically active form (60% ee) is described. Key steps in the synthesis of 1 include the osmium-catalyzed asymmetric dihydroxylation of olefin 13 [(6-but-3-enyl-2-methoxypyridin-3-yl)carbamic acid benzyl ester] and the intramolecular cyclization of protected diol 19 [(3'R)-[6-[4'-(tert-butyldimethylsilanyloxy)-3'-hydroxybutyl]-2-methoxypyridin-3-yl]carbamic acid benzyl ester] to afford the pyridinium salt 20 [(3S)-[3-(tert-butyldimethylsilanyloxymethyl)-5-methoxy-2,3-dihydro-1H-indolizin-6-yl]carbamic acid benzyl ester trifuoromethanesulfonic acid salt]. Several alternate methods to prepare olefin 13 are also discussed.